Unique ID issued by UMIN | UMIN000025405 |
---|---|
Receipt number | R000025922 |
Scientific Title | Open trial of combined use of Prasugrel for the prevention of thromoembolic complication in endovascular surgery of cerebral aneursyms |
Date of disclosure of the study information | 2016/12/26 |
Last modified on | 2020/07/08 12:37:36 |
Open trial of combined use of Prasugrel for the prevention of thromoembolic complication in endovascular surgery of cerebral aneursyms
Antithrombotic effect of Prasugrel in endovascular surgery of cerebral aneurysms
Open trial of combined use of Prasugrel for the prevention of thromoembolic complication in endovascular surgery of cerebral aneursyms
Antithrombotic effect of Prasugrel in endovascular surgery of cerebral aneurysms
Japan |
unruptured cerebral aneurysm
Neurosurgery |
Others
NO
To make antiplatelet therapy in endovascular surgery of cerebral aneurysms more effective and safe
Safety,Efficacy
Frequency of clinical thromboembolic and hemorrhagic complication
Frequency of thromboembolic complication detected by MRI(Diffusion Weighted Image) within postoperative 5 days.
Frequency of cerebral infarction and hemorrhagic complication on brain CT scan at 2~4 weeks after the endovascular surgery
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Standard prescription (Aspirin 100mg/day and Clopidogrel 75mg/day) are started 2 weeks before the endovascular surgery. Platelet function is checked on the day before the surgery. Patient with low~no response to Clopidogrel is changed to Prasugrel (loading dose 20mg, then, 3.75mg/day for 3 days). When stent is used, Prasugrel is contineud for 3 months.
Clopidogrel is continued for patient with normal response to Clopidogrel (75mg/day for 3 days). When stent is used, Clopidogrel is contineud for 3 months.
20 | years-old | <= |
80 | years-old | > |
Male and Female
1. Patients who provide informed consent for the trial.
2. Patients who are no~low response to Clopidogrel
1. Patinets who are treated with anticoagulation drugs (warfarin and NOAC) and /or antiplatelet drugs other than Aspirin and Clopidogrel.
2. Patients with abnormal platelet count (<50000/microL)
3. Patients with active bleeding (GI tract, etc)
4. Patients who are allergic to Prasugrel
5. Patients who are indicated for parent artery occlusion
6. Patients who are considered unsuitable for the trial by the responsible researcher.
60
1st name | Akiyo |
Middle name | |
Last name | Sadato |
Fujita Health University, Faculty of Medicine
Department of Neurosurgery
470-1192
Kutsukake-cho, Dengakugakubo 1-98, Toyoake city, Aichi Japan 470-1192
0562939253
asadato@fujita-hu.ac.jp
1st name | Akiyo |
Middle name | |
Last name | Sadato |
Fujita Health University, Faculty of Medicine
Department of Neurosurgery
470-1192
Kutsukake-cho, Dengakugakubo 1-98, Toyoake city, Aichi Japan 470-1192
0562-93-9253
asadato@fujita-hu.ac.jp
Fujita Health University, Faculty of Medicine
Department of Neurosurgery
Fujita Health University, Faculty of Medicine
Other
Fujita health university institusional review board
Kutsukake-cho, Dengakugakubo 1-98, Toyoake city, Aichi Japan 470-1192
0562932865
f-irb@fujita-hu.ac.jp
NO
2016 | Year | 12 | Month | 26 | Day |
Unpublished
167
Completed
2015 | Year | 12 | Month | 24 | Day |
2016 | Year | 03 | Month | 15 | Day |
2016 | Year | 09 | Month | 01 | Day |
2019 | Year | 09 | Month | 30 | Day |
2016 | Year | 12 | Month | 26 | Day |
2020 | Year | 07 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025922